ProShares UltraShort NASDAQ Biotechnology
13 hedge funds and large institutions have $19.9M invested in ProShares UltraShort NASDAQ Biotechnology in 2015 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
151% more call options, than puts
Call options by funds: $1.76M | Put options by funds: $704K
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
44% more funds holding
Funds holding: 9 → 13 (+4)
23% more capital invested
Capital invested by funds: $16.2M → $19.9M (+$3.65M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$3.83M |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$1.07M |
| 3 |
Jane Street
New York
|
+$969K |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$956K |
| 5 |
Goldman Sachs
New York
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kingfisher Capital
Charlotte,
North Carolina
|
-$1.36M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$215K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$195K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$187K |
| 5 |
Morgan Stanley
New York
|
-$21.7K |
BIS Hedge Fund Activity: Q1 2015 in Review
13 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2015, worth a combined $19.9M — up 23% from $16.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BIS positions and 5 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Healthcare Value Capital, opening a new position worth an estimated $3.83M. The largest seller was Kingfisher Capital, exiting entirely with an estimated $1.36M sold.
- 13 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2015, up from 9 in Q4 2014.
- Funds reported $19.9M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2015, up 23% quarter-over-quarter.
- 9 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2015 and 5 closed out, a net change of +4 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2015 was Healthcare Value Capital, an estimated $3.83M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2015 was Kingfisher Capital, an estimated $1.36M sold.
Based on aggregated 13F filings for Q1 2015.